SUMO-1 CRISPR Knockout and Activation Products (h)

SUMO-1 CRISPR Knockout and Activation Plasmids (h) designed to edit, knockdown or upregulate human SUMO-1 gene expression

SUMO1 - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated.

Sumo 1 (SUMO1) Human Gene Knockout Kit (CRISPR)

SUMO-4 CRISPR Knockout and Activation Products (h)

Frontiers Identification of UBE2I as a Novel Biomarker in ccRCC Based on a Large-Scale CRISPR-Cas9 Screening Database and Immunohistochemistry

Frontiers SUMOylation Connects Cell Stress Responses and Inflammatory Control: Lessons From the Gut as a Model Organ

IJMS, Free Full-Text

A primate-and tissue-specific SUMO variant, SUMO5, forms NBs. (A) SUMO5

Sumoylation of Cas9 at lysine 848 regulates protein stability and DNA binding

are ready to use gene editing systems designed to knockout or upregulate gene expression of human Gfi-1

Gfi-1 CRISPR Knockout and Activation Products (h)

Alternative splicing of the SUMO1/2/3 transcripts affects cellular SUMOylation and produces functionally distinct SUMO protein isoforms

are ready to use gene editing systems designed to knockout or upregulate gene expression of human Bcr

Bcr CRISPR Knockout and Activation Products (h)

Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing

Cell Lines For Studying Sumoylation

CRISPR–Cas9-mediated base-editing screening in mice identifies DND1 amino acids that are critical for primordial germ cell development

The SUMO–NIP45 pathway processes toxic DNA catenanes to prevent mitotic failure

SUMO-activated target traps (SATTs) enable the identification of a comprehensive E3-specific SUMO proteome